| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Medical Research Center, New Orleans
2 From the Foothill Family Clinic, Salt Lake City, Utah
3 From the Allergy Immunology Asthma, Inc, Stockton, Calif
4 From the Edward Hines, Jr. Veterans Affairs (VA) Hospital/Loyola University of Chicago, Hines, Ill.
5 From the VA Outpatient Clinic, Boston
6 From the Rhône-Poulenc Rorer Research and Development, Collegeville, Pa.
Study objective: Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB).
Design: Multicenter, double-blind, randomized study.
Setting: Sixty-eight private offices and outpatient clinics in the United States and Canada.
Patients: Seven hundred ninety-eight adults with ABECB, as confirmed by the acute onset of new (or worsened from the immediate premorbid state) cough and sputum production.
Interventions: Randomization 1:1 to sparfloxacin, 400 mg on day 1, then 200 mg once daily, or ofloxacin, 400 mg twice daily, with matching comparator placebos, given concurrently for 10 consecutive days.
Results: The primary efficacy parameter was overall response in the bacteriologically evaluable population. Overall success rates in this population were 85.3% and 89.3% for sparfloxacin and ofloxacin, respectively. The two-sided 95% confidence interval was 
9.9, 1.9, indicating that sparfloxacin was statistically equivalent to ofloxacin. The all-treated population analysis was similar to that in the evaluable population. Bacterial eradication rates were similar in both treatment groups for Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Enterobacter cloacae, and Staphylococcus aureus. The frequency of adverse events overall was comparable in the two treatment groups. The sparfloxacin group had a lower frequency of digestive and nervous system adverse events, but a higher frequency of photosensitivity reactions than the ofloxacin group.
Conclusions: Once-daily oral treatment with 200 mg sparfloxacin (after initial 400 mg dose) is as effective as twice-daily treatment with 400 mg ofloxacin in patients with ABECB.
Key Words: acute bacterial exacerbations of chronic bronchitis • drug therapy • ofloxacin • sparfloxacin
Submitted on May 28, 1997
Accepted on December 2, 1997
This article has been cited by other articles:
|
|
 |
|
  M. Miravitlles Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur. Respir. J., July 1, 2002; 20(36_suppl): 9S - 19s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miravitlles, C. Murio, and T. Guerrero Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis Eur. Respir. J., May 1, 2001; 17(5): 928 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sethi and T. F. Murphy Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review Clin. Microbiol. Rev., April 1, 2001; 14(2): 336 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Cubbon and R. G. Masterton New quinolones--a fresh answer to the pneumococcus J. Antimicrob. Chemother., December 1, 2000; 46(6): 869 - 872. [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Hirschmann Do Bacteria Cause Exacerbations of COPD? Chest, July 1, 2000; 118(1): 193 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Stockley, C. O'Brien, A. Pye, and S. L. Hill Relationship of Sputum Color to Nature and Outpatient Management of Acute Exacerbations of COPD Chest, June 1, 2000; 117(6): 1638 - 1645. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
